JP2013522216A - 非水性高濃度減粘懸濁製剤 - Google Patents
非水性高濃度減粘懸濁製剤 Download PDFInfo
- Publication number
- JP2013522216A JP2013522216A JP2012557197A JP2012557197A JP2013522216A JP 2013522216 A JP2013522216 A JP 2013522216A JP 2012557197 A JP2012557197 A JP 2012557197A JP 2012557197 A JP2012557197 A JP 2012557197A JP 2013522216 A JP2013522216 A JP 2013522216A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- vehicle
- viscosity
- bioactive molecule
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 192
- 238000009472 formulation Methods 0.000 claims abstract description 184
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000003981 vehicle Substances 0.000 claims description 77
- 239000002245 particle Substances 0.000 claims description 73
- 235000011803 sesame oil Nutrition 0.000 claims description 66
- 239000008159 sesame oil Substances 0.000 claims description 66
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 62
- 230000000975 bioactive effect Effects 0.000 claims description 62
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 62
- 229940093471 ethyl oleate Drugs 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 238000002347 injection Methods 0.000 claims description 55
- 239000007924 injection Substances 0.000 claims description 55
- 230000002209 hydrophobic effect Effects 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 239000003638 chemical reducing agent Substances 0.000 claims description 24
- 239000012749 thinning agent Substances 0.000 claims description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000011521 glass Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 238000010304 firing Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 22
- 229940098773 bovine serum albumin Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 239000002562 thickening agent Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000012530 fluid Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- -1 polytrimethylene carbonate Polymers 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 239000013011 aqueous formulation Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002687 nonaqueous vehicle Substances 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940057917 medium chain triglycerides Drugs 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229950011087 perflunafene Drugs 0.000 description 3
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000012514 monoclonal antibody product Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- UDEWPOVQBGFNGE-UHFFFAOYSA-N propyl benzoate Chemical compound CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DVMSVWIURPPRBC-UHFFFAOYSA-N 2,3,3-trifluoroprop-2-enoic acid Chemical compound OC(=O)C(F)=C(F)F DVMSVWIURPPRBC-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DUAYDERMVQWIJD-UHFFFAOYSA-N 2-n,2-n,6-trimethyl-1,3,5-triazine-2,4-diamine Chemical compound CN(C)C1=NC(C)=NC(N)=N1 DUAYDERMVQWIJD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LNUDZOHDUVPVPO-UHFFFAOYSA-N 3,3-difluoro-2-(trifluoromethyl)prop-2-enoic acid Chemical compound OC(=O)C(=C(F)F)C(F)(F)F LNUDZOHDUVPVPO-UHFFFAOYSA-N 0.000 description 1
- MLLAPOCBLWUFAP-UHFFFAOYSA-N 3-Methylbutyl benzoate Chemical compound CC(C)CCOC(=O)C1=CC=CC=C1 MLLAPOCBLWUFAP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FEXQDZTYJVXMOS-UHFFFAOYSA-N Isopropyl benzoate Chemical compound CC(C)OC(=O)C1=CC=CC=C1 FEXQDZTYJVXMOS-UHFFFAOYSA-N 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- KYZHGEFMXZOSJN-UHFFFAOYSA-N benzoic acid isobutyl ester Natural products CC(C)COC(=O)C1=CC=CC=C1 KYZHGEFMXZOSJN-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- LSLWNAOQPPLHSW-UHFFFAOYSA-N butan-2-yl benzoate Chemical compound CCC(C)OC(=O)C1=CC=CC=C1 LSLWNAOQPPLHSW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000010632 citronella oil Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003537 desflurane Drugs 0.000 description 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002018 neem oil Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Abstract
Description
本願は、2010年3月9日出願の米国仮出願第61/311,896号に対する優先権を主張し、これを参照することにより本明細書に組み込む。
本発明は、非水性高濃度減粘懸濁製剤、並びにその製造及び使用方法に関する。
a.疎水性剤及び減粘剤を含むビヒクルと、
b.生物活性分子と、を含む非水性高濃度懸濁製剤である。
非水性ビヒクルのための減粘剤のスクリーニング
減粘剤を0.2体積%〜50体積%の濃度でゴマ油に添加する。全ての減粘剤は、GRAS(一般に安全であると認められている)材料であった。20mLの密閉シンチレーションバイアルに混合物を入れ、30秒間ボルテックスし、任意の不混和性について目視検査した。減粘剤の幾つかは、ゴマ油と混和しないことが見出されたので、更なるスクリーニングは行わなかった。表3は、例示的な減粘剤とゴマ油との混和性を示す。Y及びNは、それぞれ、試験した減粘剤が試験した濃度でゴマ油と混和性であった又はなかったことを示す。
非水性高濃度低粘度製剤の調製
生物活性分子の粒子の調製
凍結乾燥:
ウシ血清アルブミン(BSA)(Sigma−Aldrich,St.Louis,MO,USA)及びヒト抗TNFαモノクローナル抗体(mAb)を6.5mMのリン酸ナトリウムバッファ(pH 6.0)に65mg/mLのタンパク質濃度で溶解させた。任意で、スクロース等の薬学的に許容可能な賦形剤及びTween 80(又はポリソルベート80、PS−80)を、それぞれ最終溶液中のスクロース及びTween 80濃度が0〜9.0%及び0〜0.01%(%w/v)になるようにタンパク質溶液に添加した。標準的なプロトコールを用いてタンパク質溶液を凍結乾燥させた。
噴霧乾燥プロセスを用いてウシ血清アルブミン(BSA)(Sigma−Aldrich,St.Louis,MO,USA)及びヒト抗TNFαモノクローナル抗体の粒子を調製した。以下のプロセスパラメータで、Yamato Mini噴霧乾燥機を用いて製剤(表5)を噴霧乾燥させた:空気の噴霧:13.8kPa(2psi)、入口温度:120℃、吸引器ダイアル:7.5、溶液ポンプ:2〜4、主空気弁:275.8〜310.3kPa(40〜45psi)。噴霧乾燥された生物活性分子微粒子の平均直径(D50)を、レーザー回折粒度分析器(Malvern Mastersizer 2000,Malvern)により測定し、1〜20μmの粒度範囲の粒子を得た。例示的な調製品を表5に示す。
ゴマ油を酸化アルミニウム粉末で洗浄して過酸化物濃度を低下させ、次いで、滅菌した0.2μmのPTFEフィルタを通して濾過した。0.2〜85体積%(%v/v)の濃度で減粘剤をゴマ油に添加した、又は場合によってはゴマ油を用いなかった。幾つかの製剤では、約0.2〜10体積%でエタノールをビヒクルに添加した。混合物を密閉容器に入れ、室温で1時間混合して、均質な溶液を形成した。表4は、調製した非水性ビヒクルを示す。
調製された非水性ビヒクルを、凍結乾燥又は噴霧乾燥により調製された生物活性分子の粒子と混合した。ステンレススチールのスパチュラブレードを備える撹拌機を用いて、50〜1000rpmで5〜30分間室温にて、粒子をビヒクルにブレンドした。約1〜50重量%の粒子をロードして、最終製剤中のタンパク質濃度を約10〜500mg/mLにした。均質な懸濁液を形成した後、製剤をガラス注射器に充填した。注射前、冷蔵温度(4℃)で製剤を保存した。表6は、調製された製剤を示す。
非水性ビヒクル中における凍結乾燥した生物活性分子の安定性
オレイン酸エチル(EO)又は中鎖トリグリセリド(MCT;LABRAFAC(商標)Lipophile WL 1349,Gattefosse,France)をゴマ油(SO)に2〜50体積%の濃度で添加した。混合物を、密閉した20mLのシンチレーションバイアルに入れ、30秒間ボルテックスした。混合が完了した後、凍結乾燥した抗TNFα抗体粉末を3mLのバキュテイナーチューブに量り入れ、最終タンパク質含量が10又は20%(%w/w)になるように適切な量のビヒクルをチューブに添加したが、これは、それぞれ、53.6又は107.2mg/mLの抗TNFα抗体濃度に相当する。
高濃度製剤の射出性は、ビヒクルの組成、タンパク質濃度、及び粒度によって影響を受ける。
ピストン移動力(例えば、射出力)の測定は、本発明の非水性高濃度懸濁製剤の射出性に対する様々なパラメータの効果を測定するためのアセスメントとして用いられた。
20%(%w/w)BSA及び20%(%w/w)抗TNFα抗体製剤の射出性を、Zwick/Roell(Model 2005)試験機を用いて、ゲージ針を通して懸濁液を押し出すのに必要な力を測定することにより評価した。水中100mg/mLのBSAを噴霧乾燥させることによりBSA粒子を調製し、65mg/mLのタンパク質、55mg/mLのスクロース、10mMのL−ヒスチジン、0.01%のPS−80(pH 5.5)を噴霧乾燥させることにより、抗TNFα mAb粒子を調製した。漸増量(体積による)の減粘剤オレイン酸エチル(0%、3%、9.5%、17%、20%、25%、28%、30%、40%、50%、75%、85%、又は100%(%v/v))を含有するゴマ油と上述のタンパク質粒子とを混合することによりタンパク質製剤を調製した。次いで、調製した製剤を、BD(Becton,Dickinson and Company,NJ)注射器0.5インチ26 1/2ゲージの針を備える1mLの剛性針シールドガラス予充填可能注射器であるBD Hypak SCF(商標)(製品名PIR6−001 SCF1MLL 26GA 1/2 RNSFM27 EB LTP.8268589)にロードした。約0.5ccの製剤を注射器に充填し、特に指定しない限り、射出速度を約250mm/分に設定し、ピストン移動力を記録した。射出試験は、室温で実施した。
射出力は、非水性懸濁製剤中のタンパク質濃度によって影響を受けた。図3Aは、製剤の射出力における、8.2μmの抗TNFα粒子抗体濃度の増加(20〜40%(%w/w);108.3〜216.7mg/mL)及び減粘剤の量の増加の複合効果を示す。X軸は、各実験で用いられた抗TNFα抗体の濃度を示す。EO/SO/50/50において最高30%のmAb濃度を用いることにより、42.8Nの射出力が得られた。この抗体濃度における射出力は、ビヒクルとして100% EOを用いることにより20.5Nまで低下させることができた。図3Bは、射出力及び粘度の両方における、EO/SO/50/50製剤中の抗TNFα mAb(0〜40%(%w/w;0216.7mg/mL)の濃度上昇の効果を示す。図3Cは、100% SO、EO/SO/50/50、及び100% EOビヒクル中のBSA(粒度2μm、0〜40%(%w/w);0〜400mg/mL)の濃度上昇の効果を示す。約45N以下に射出力を低下させるために、製剤は、ビヒクル中に約20%(%w/w)以下のタンパク質及び少なくとも28%のEO、ビヒクル中に30%以下のタンパク質及び少なくとも50%のEO、又は100% EO中に約40%以下のタンパク質のタンパク質濃度を含有し得る。また、実施した実験は、非水性高濃度懸濁製剤の射出力及び粘度が相関していることを示した。図4aは、20%(%w/w)抗TNFα mAb懸濁製剤における相関を示す。図4bは、試験した全ての抗TNFα mAb懸濁製剤における相関を示す。したがって、射出力は、粘度及び射出性の尺度として用いることができる。非水性高濃度懸濁製剤におけるタンパク質濃度及び減粘剤の量の両方を適切に変化させることにより、製剤の射出性に正の影響を与えられる。
射出性に対する粒度の効果を、試験した製剤の射出力に対する様々な粒度の効果を測定することにより評価した。1〜50%(%w/w)(10〜500mg/mL)の範囲にわたって2μm及び13μmのBSA粒子を含有する製剤をEO/SO/50/50のビヒクル中で調製した。これら製剤では、射出力はタンパク質濃度の上昇とともに上昇し、粒度の増加とともに低下する(図5)。例えば、45N以下の射出力を達成するために、EO/SO/50/50中における40%(%w/w)の粒度13μmのタンパク質製剤を用いることができる。固相の粒度を増加させながら懸濁液中の粒子の質量を一定に維持することにより、系における粒子数が減少する。したがって、粒度の高い懸濁液は、粒子−粒子相互作用が少なく、流動に対する抵抗が低下し、射出力が低下する。結果は、40%(%w/w)等の高タンパク質濃度では、非水性懸濁製剤における粒度の選択が、射出力、ひいては製剤の射出性に著しい影響を与えることを示す。例えば、40%(5w/w)の13μmのタンパク質粒子を含む製剤の射出力は40.5Nであるが、2μmタンパク質粒子を含む同製剤は、57Nの射出力を有する。したがって、本発明の懸濁製剤の射出性は、タンパク質濃度及び粒度に加えて、製剤中の減粘剤の量を最適化することにより改善することができる。
非水性高濃度懸濁製剤の粘度は、剪断速度を増加させることにより低下し得る。
様々な剪断速度における粘度に対するビヒクルの選択及びタンパク質濃度の効果について調べた。EO/SO/50/50又はSO中に1〜40%(%w/w)の抗TNFα抗体を含有する製剤290μLを、40mm、1°アクリル製円錐形状を備えるAR2000レオメーター(TA Instruments)にピペットで入れた。剪断速度を約8s-1から5000s-1に増加させたときの各製剤についての粘度スキャンを25℃で測定した。
射出力を変化させるための射出速度の調整
EO中40〜50%(%w/w)(400〜500mg/mL)の2μm及び13μmのBSA粒子(図7A、7B)、並びにEO/SO/50/50中20〜40%(%w/w)(108.33〜216.67mg/mL)の抗TNFα抗体(図7C)の射出力を様々な射出速度を用いて評価した。射出速度は、タンパク質濃度依存的な方法で射出力に影響を与えた。40%(%w/w)BSAでは、射出力は、射出速度にそれほど依存していなかった。しかし、50%(%w/w)のBSA濃度では、250mm/分から50mm/分に射出速度を低下させると、射出力は111.4Nから32.4Nに著しく低下した(図7A)。また、射出速度による射出力に対する効果は、粒度によっても影響を受けた。より大きな粒度を有する製剤の射出力は、射出速度によりそれほど影響を受けなかったが、より小さな粒度を有する製剤の射出力は、射出速度によって著しく影響を受けた(図7B)。射出速度50〜250mm/分で13μmのBSA粒子を利用すると、45N以下の射出速度が得られた。また、射出速度は、抗TNFα抗体製剤の射出力にも影響を与え、射出速度を低下させると射出力も低下した(図7C)。
Claims (18)
- a.疎水性剤及び減粘剤を含むビヒクルと、
b.生物活性分子と、
を含む非水性高濃度懸濁製剤。 - 前記疎水性剤がゴマ油である、請求項1に記載の製剤。
- 前記減粘剤が、オレイン酸エチル、リノール酸、プロピオン酸、クエン酸トリエチル、イソプロピルアルコール、エタノール、セバシン酸ジエチル、又はミリスチン酸イソプロピルである、請求項1に記載の製剤。
- 前記ビヒクル中の前記減粘剤の量が、前記ビヒクルの0.2体積%〜85体積%(%v/v)である、請求項1に記載の製剤。
- 前記生物活性分子が、前記製剤の約0.5重量%〜約50重量%(%w/w)で存在する、請求項1に記載の製剤。
- 前記製剤の射出力が45ニュートン(N)以下であり、前記射出力が、射出速度250mm/分で、0.5インチ26 1/2ゲージの針を備える、内径0.25インチの1mLの剛性針シールドガラス注射器を用いて測定される、請求項1に記載の製剤。
- 前記生物活性分子の粒度が、2μm〜13μmである、請求項1に記載の製剤。
- 前記生物活性分子が、モノクローナル抗体である、請求項1に記載の製剤。
- 少なくとも1ヶ月間40℃で安定である、請求項1に記載の製剤。
- a.ゴマ油及びオレイン酸エチルを含むビヒクルと、
b.生物活性分子と、
を含む非水性高濃度懸濁製剤。 - 前記ビヒクル中の前記オレイン酸エチルの量が、ビヒクルの0.2体積%〜85体積%(%v/v)である、請求項10に記載の製剤。
- 前記生物活性分子が、前記製剤の約0.5重量%〜約50重量%(%w/w)で存在する、請求項10に記載の製剤。
- 前記製剤の射出力が45ニュートン(N)以下であり、前記射出力が、射出速度250mm/分で、0.5インチ26 1/2ゲージの針を備える、内径0.25インチの1mLの剛性針シールドガラス注射器を用いて測定される、請求項1に記載の製剤。
- 前記生物活性分子の粒度が、2μm〜13μmである、請求項10に記載の製剤。
- 前記タンパク質が、モノクローナル抗体である、請求項10に記載の製剤。
- 疎水性剤を含むビヒクル中に50mg/mL以上のタンパク質を含有する製剤の射出力を約45ニュートン(N)以下に低下させる方法であって、
a.疎水性剤を含む前記ビヒクルに少なくとも28体積%の減粘剤を添加する工程、又は
b.約2μm〜13μmの粒度を有するタンパク質粒子を利用して、製剤を調製する工程を含み、
前記射出力が、射出速度250mm/分で、0.5インチ26 1/2ゲージの針を備える、内径0.25インチの1mLの剛性針シールドガラス注射器を用いて測定される方法。 - 前記疎水性ビヒクルが、ゴマ油であり、前記減粘剤が、オレイン酸エチルである、請求項16に記載の方法。
- 生物活性分子の非水性高濃度懸濁製剤を製造する方法であって、
a.生物活性分子を提供する工程と、
b.疎水性剤を提供する工程と、
c.減粘剤を提供する工程と、
d.前記疎水性剤と前記減粘剤とを混合して、ビヒクルを形成する工程と、
e.工程dで形成されたビヒクルに50mg/mL以上の濃度で前記生物活性分子を添加する工程と、
を含む製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31189610P | 2010-03-09 | 2010-03-09 | |
US61/311,896 | 2010-03-09 | ||
PCT/US2011/027677 WO2011112669A1 (en) | 2010-03-09 | 2011-03-09 | Non-aqueous high concentration reduced viscosity suspension formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013522216A true JP2013522216A (ja) | 2013-06-13 |
JP5837519B2 JP5837519B2 (ja) | 2015-12-24 |
Family
ID=44560215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012557197A Active JP5837519B2 (ja) | 2010-03-09 | 2011-03-09 | 非水性高濃度減粘懸濁製剤 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2544721B1 (ja) |
JP (1) | JP5837519B2 (ja) |
CN (1) | CN103096934A (ja) |
CA (1) | CA2792517C (ja) |
ES (1) | ES2659079T3 (ja) |
IL (1) | IL221801A (ja) |
WO (1) | WO2011112669A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014510077A (ja) * | 2011-03-09 | 2014-04-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗体の非水性高濃度減粘懸濁製剤 |
JP2016535775A (ja) * | 2013-11-05 | 2016-11-17 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ゴマ油ベースの注射製剤 |
JP2020534260A (ja) * | 2017-09-19 | 2020-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 粒子の形成を低減する方法及びそれにより形成される組成物 |
US12018091B2 (en) | 2020-10-28 | 2024-06-25 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
JP6503349B2 (ja) | 2013-07-23 | 2019-04-17 | ノバリック ゲーエムベーハー | 安定化された抗体組成物 |
EP3624846A1 (en) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001503029A (ja) * | 1996-09-18 | 2001-03-06 | バイエル・アクチエンゲゼルシヤフト | アベルメクチンおよびミルベマイシンの注射製剤 |
JP2008525457A (ja) * | 2004-12-23 | 2008-07-17 | アルザ・コーポレーシヨン | 注射可能な非水性懸濁液 |
JP2012508744A (ja) * | 2008-11-16 | 2012-04-12 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 高濃度の低粘度懸濁液 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639587A (en) * | 1969-11-07 | 1972-02-01 | Eastman Kodak Co | Medicinal compositions for administration to animals and process for administering same |
IN184589B (ja) * | 1996-10-16 | 2000-09-09 | Alza Corp | |
KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
DE10330235A1 (de) * | 2003-07-04 | 2005-01-20 | Bayer Healthcare Ag | Neues Eimeria Gen und Protein sowie deren Verwendung |
US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
CA2667655A1 (en) * | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
-
2011
- 2011-03-09 CA CA2792517A patent/CA2792517C/en active Active
- 2011-03-09 WO PCT/US2011/027677 patent/WO2011112669A1/en active Application Filing
- 2011-03-09 JP JP2012557197A patent/JP5837519B2/ja active Active
- 2011-03-09 CN CN2011800132537A patent/CN103096934A/zh active Pending
- 2011-03-09 EP EP11753982.5A patent/EP2544721B1/en active Active
- 2011-03-09 ES ES11753982.5T patent/ES2659079T3/es active Active
-
2012
- 2012-09-06 IL IL221801A patent/IL221801A/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001503029A (ja) * | 1996-09-18 | 2001-03-06 | バイエル・アクチエンゲゼルシヤフト | アベルメクチンおよびミルベマイシンの注射製剤 |
JP2008525457A (ja) * | 2004-12-23 | 2008-07-17 | アルザ・コーポレーシヨン | 注射可能な非水性懸濁液 |
JP2012508744A (ja) * | 2008-11-16 | 2012-04-12 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 高濃度の低粘度懸濁液 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014510077A (ja) * | 2011-03-09 | 2014-04-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗体の非水性高濃度減粘懸濁製剤 |
JP2016535775A (ja) * | 2013-11-05 | 2016-11-17 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ゴマ油ベースの注射製剤 |
JP2019052166A (ja) * | 2013-11-05 | 2019-04-04 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ゴマ油ベースの注射製剤 |
JP2020534260A (ja) * | 2017-09-19 | 2020-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 粒子の形成を低減する方法及びそれにより形成される組成物 |
JP7301043B2 (ja) | 2017-09-19 | 2023-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 粒子の形成を低減する方法及びそれにより形成される組成物 |
US12018091B2 (en) | 2020-10-28 | 2024-06-25 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
Also Published As
Publication number | Publication date |
---|---|
CN103096934A (zh) | 2013-05-08 |
EP2544721A4 (en) | 2013-12-04 |
IL221801A (en) | 2017-04-30 |
WO2011112669A1 (en) | 2011-09-15 |
EP2544721A1 (en) | 2013-01-16 |
CA2792517A1 (en) | 2011-09-15 |
CA2792517C (en) | 2020-03-24 |
JP5837519B2 (ja) | 2015-12-24 |
EP2544721B1 (en) | 2017-12-06 |
ES2659079T3 (es) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5881748B2 (ja) | 抗体の非水性高濃度減粘懸濁製剤 | |
US9072668B2 (en) | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies | |
JP5837519B2 (ja) | 非水性高濃度減粘懸濁製剤 | |
JP5078217B2 (ja) | 注入可能なデポー組成物およびそれらの使用 | |
JP2010509243A5 (ja) | ||
WO2008092084A2 (en) | Injectable non-aqueous suspension with high concentration of therapeutic agent | |
JP2012508744A5 (ja) | ||
JP2012508744A (ja) | 高濃度の低粘度懸濁液 | |
KR102438425B1 (ko) | 풀베스트란트 제제 및 그의 사용 방법 | |
Marschall et al. | Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins | |
BR112021009463A2 (pt) | formulação de proteína de alta concentração | |
CA3018473A1 (en) | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody | |
EP4065082A1 (en) | Suspension comprising a protein particle suspended in a non-aqueous vehicle | |
JP2021008406A (ja) | 改良型ヒト化抗ヒトα9インテグリン抗体含有医薬組成物 | |
CA3231500A1 (en) | Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5837519 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |